The Granzyme B Inhibitor SERPINB9 (Protease Inhibitor 9) Circulates in Blood and Increases on Primary Cytomegalovirus Infection after Renal Transplantation
Divisions of 1Clinical Immunology and Rheumatology and 2Nephrology, Department of Internal Medicine, and 3Department of Experimental Immunology, Academic Medical Center, 4Department of Immunopathology, Sanquin Research at the Central Laboratory Bloodbank, and 5Department of Clinical Chemistry, Free University Medical Center, Amsterdam, The Netherlands
SERPINB9 is the only known human intracellular inhibitor of granzyme B (GrB), the effector molecule in immunity against cytomegalovirus (CMV) and in renal allograft rejection. Therefore, using specific enzyme‐linked immunosorbent assays, we addressed the presence of circulating SERPINB9 during primary CMV infection, subclinical rejection, acute rejection, and uncomplicated posttransplantation course. Soluble (s) SERPINB9 circulates in blood and increases on primary CMV infection. This increase was significantly higher in symptomatic than in asymptomatic patients. In contrast, sSERPINB9 levels did not change in response to subclinical or acute rejection. We demonstrated the presence of circulating sSERPINB9/sGrB complexes, which suggests that SERPINB9 has extracellular functions as well.
Received 6 March 2005; accepted 20 June 2005; electronically published 18 October 2005.
Cited by
Online publication date: 1-Jun-2009.
CrossRef
Online publication date: 1-Aug-2008.
CrossRef
Online publication date: 1-May-2008.
CrossRef
Online publication date: 1-Aug-2006.
CrossRef
-
Potential conflicts of interest: none reported.
Financial support: Academic Medical Center, University of Amsterdam.





